The potential of cfDNA/ctDNA can be investigated as biomarkers for predicting the therapeutic outcome in unresectable hepatocellular carcinoma (u-HCC) patients treated with anti-PD-L1/VEGF therapy (Matsumae et al., 2022). Here, CD274 is linked to hepatocellular carcinoma.